Finance

Lists
Q2 2026 earnings • released • EPS beat +39.99% • Revenue beat +12.22%
See results
REGN:NASDAQ
Regeneron Pharmaceuticals Inc
$762.63
+3.29%
(+24.29) 1D
$777.11
+1.90% (+14.48)
Pre-market
Closed: Jul 31, 4:00:00 PM GMT-4  ·   USD
All symbols
SymbolPriceChange% Change
Generating top insights for REGN...
Open
$726.69
High
$764.75
Low
$724.79
Mkt. cap
78.52B
Avg. vol.
929.78K
Volume
1.12K
Dividend
0.49%
Quarterly dividend
$0.94
Ex-dividend date
Aug 18, 2026
P/E ratio
18.59
52-wk high
$821.11
52-wk low
$541.00
EPS
$41.03
Beta
0.24
Shares outstanding
101.14M
No. of employees
15K
Open
$726.69
High
$764.75
Low
$724.79
Mkt. cap
78.52B
Avg. vol.
929.78K
Volume
1.12K
Dividend
0.49%
Quarterly dividend
$0.94
Ex-dividend date
Aug 18, 2026
P/E ratio
18.59
52-wk high
$821.11
52-wk low
$541.00
EPS
$41.03
Beta
0.24
Shares outstanding
101.14M
No. of employees
15K
News stories
From sources across the web
Profile
Regeneron Pharmaceuticals, Inc. is an American biotechnology company headquartered in Westchester County, New York. The company was founded in 1988. Originally focused on neurotrophic factors and their regenerative capabilities, giving rise to its present name; the company has since expanded operations into the study of both cytokine and tyrosine kinase receptors, which gave rise to their first product, which is a VEGF-trap. Wikipedia
About Regeneron Pharmaceuticals Inc
CEOLeonard Schleifer
Employees15.3K
Founded1988
HeadquartersTarrytown, New York, United States
SectorBiotechnology
Websiteregeneron.com
Analyst ratings
Based on 21 analysts giving stock ratings to REGN in the past 3 months
Buy
Buy
14
Hold
7
Sell
0
12-month forecast
Based on 21 Wall Street analysts offering 12 month price targets for REGN in the last 3 months.
Highest
Current $762.63
$1,000.00 (+31.13%)
Average
$825.14 (+8.20%)
Lowest
$641.00 (-15.95%)
Analyst
Recommendation
Action
Price target
Projected
Date
Geoff Meacham
Citi
Hold
Maintained
$740.00
-3%
08/03/2026
Evan Seigerman
BMO Capital
Buy
Maintained
$800.00
+4.9%
07/31/2026
Brian Abrahams
RBC Capital
Hold
Reiterated
$737.00
-3.4%
07/30/2026
Salveen Richter
Goldman Sachs
Buy
Maintained
$972.00
+27.5%
07/30/2026
Louise Chen
Scotiabank
Hold
Maintained
$770.00
+1%
07/31/2026
Carter Gould
Cantor Fitzgerald
Buy
Maintained
$795.00
+4.2%
07/30/2026
Gregory Renza
Truist Financial
Buy
Maintained
$772.00
+1.2%
07/31/2026
Terence Flynn
Morgan Stanley
Hold
Maintained
$758.00
-0.6%
07/31/2026
Brian Skorney
Robert W. Baird
Hold
Maintained
$761.00
-0.2%
07/31/2026
Mohit Bansal
Wells Fargo
Hold
Maintained
$750.00
-1.7%
07/31/2026
Eliana Merle
Barclays
Buy
Maintained
$917.00
+20.2%
07/31/2026
Tazeen Ahmad
Bank of America Securities
Buy
Reiterated
$891.00
+16.8%
07/30/2026
Tyler Van Buren
TD Cowen
Buy
Maintained
$960.00
+25.9%
07/30/2026
John Newman
Canaccord Genuity
Buy
Maintained
$875.00
+14.7%
07/22/2026
Yatin Suneja
Guggenheim
Buy
Reiterated
$1,000.00
+31.1%
07/21/2026
Biren Amin
Piper Sandler
Buy
Reiterated
$854.00
+12%
07/09/2026
Rajesh Kumar
HSBC
Buy
Maintained
$800.00
+4.9%
07/06/2026
Alexandria Hammond
Wolfe Research
Buy
Reiterated
$860.00
+12.8%
05/18/2026
Cory Kasimov
Evercore ISI
Buy
Maintained
$825.00
+8.2%
05/18/2026
Chris Schott
J.P. Morgan
Buy
Reiterated
$850.00
+11.5%
05/18/2026
David Risinger
Leerink Partners
Hold
Downgraded
$641.00
-15.9%
05/18/2026
Nicholas Lorusso
TD Cowen
Buy
Maintained
$960.00
+25.9%
05/06/2026
Matthew Biegler
Oppenheimer
Buy
Reiterated
$865.00
+13.4%
04/30/2026
William Pickering
Bernstein
Buy
Maintained
$921.00
+20.8%
04/08/2026
Akash Tewari
Jefferies
Buy
Maintained
$890.00
+16.7%
03/11/2026
Christopher Raymond
Raymond James
Buy
Maintained
$870.00
+14.1%
01/30/2026
Last report
Jul 30, 2026
Fiscal period
Q2 2026
EPS / Est. (USD)
$14.29 / $10.21
+39.99%beat
Revenue / Est. (USD)
4.29B / 3.82B
+12.22%beat
Fiscal Q2 2026 earnings call
Waiting for the earnings call
At a glance
Insights from the latest news and reports
Previous reportsAll values in USD
Loading Previous Earnings...
Income statement
Revenue
Net income
All values in USD
Sep 2025
Dec 2025
Mar 2026
Jun 2026
Revenue
3.75B
3.88B
3.61B
4.29B
Cost of goods sold
2.00B
2.21B
2.21B
576.50M
Cost of revenue
2.00B
2.21B
2.21B
576.50M
Research and development expenses
-
-
-
-
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
657.80M
775.00M
647.70M
662.10M
Operating expense
647.80M
775.00M
647.70M
2.29B
Total operating expenses
2.64B
2.99B
2.86B
2.87B
Operating income
1.11B
898.60M
744.80M
1.42B
Other non operating income
3.00M
958.50M
-7.30M
245.30M
EBT including unusual items
1.76B
1.04B
831.20M
1.53B
EBT excluding unusual items
1.27B
2.04B
908.10M
1.65B
Income tax expense
303.30M
199.10M
104.00M
230.90M
Effective tax rate
17.20%
19.08%
12.51%
15.11%
Other operating expenses
-10.00M
-
-
-
Net income
1.46B
844.60M
727.20M
1.30B
Net profit margin
38.89%
21.74%
20.17%
30.23%
Earnings per share
11.83
11.44
9.47
14.29
Interest and investment income
175.10M
193.30M
183.50M
-
Interest expense
-19.30M
-12.20M
-12.90M
-11.00M
Net interest expenses
155.80M
181.10M
170.60M
-11.00M
Depreciation and amortization charges
-
-
-
-
EBITDA
1.25B
1.04B
868.00M
1.54B
Gain or loss from assets sale
-
-
-
-
Insider transactions
Insider transactions data is drawn from third-party sources. Learn more
Insider
Position
Type
Date
Shares
Amount
Page 1
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer

Research

What's on your mind?
What's going on with the markets today?
Explore what’s possible
Create a portfolio
Create a task
Deep Search
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer
Google apps